Financial Performance Update

Restated Financials Post-Merger

The merger with Dhanuka Laboratories became effective on July 10, 2026, with an appointed date of April 1, 2024. Accordingly, FY25 and FY26 results have been restated to reflect combined operations:

  • FY26 revenue: INR1,233 crores (compared to INR1,398 crores in FY25)
  • FY26 gross margin: 32% (compared to 36% in FY25)
  • Combined employee and other operating expenses: INR353 crores in both FY26 and FY25

Q1 FY27 Financial Results

  • Revenue from operations: INR304 crores (15% YoY growth from INR263 crores in Q1 FY26)
  • Gross margin: 33% (3 percentage point improvement from 30% in Q1 FY26)
  • EBITDA: INR25 crores (significant improvement from INR10 crores in Q1 FY26)
  • AMS division revenue: INR5 crores with EBITDA loss of INR0.5 crores

Operational and Strategic Updates

Market Conditions

The cephalosporin business faced challenging conditions in FY26 with 15-20% declines in both volumes and pricing across important products and markets. The industry continues to face overcapacities leading to competitive pressures.

Exblifep (Cefepime-Enmetazobactam) Commercialization

  • Russia: Signed licensing arrangement with estimated 10-year value of USD178 million (long-term value, not current revenue)
  • Europe: Significant volume growth - 300% in Q3 FY26, 170% in Q4 FY26, 50% in Q1 FY27
  • Middle East and Africa: Registration completed in South Africa, coverage across GCC markets
  • Advanced discussions: South America, Mexico, Philippines, Thailand, Morocco, Australia
  • Ongoing discussions: US and China markets
  • Current manufacturing: Domestic market supply manufactured by Orchid; international sales through CMO in China initially

Cefiderocol Project

  • Project on schedule despite equipment rerouting challenges from China through Italy
  • Target commissioning: December 2026
  • Validation and initial batches: January-March 2027
  • Commercial launch subject to DCGI approval process
  • GARDP has floated global RFP process for broader market access across 135 countries
  • Target WHO PQ filing which takes approximately 2 years

7-ACA Project

  • Commissioning and first commercial batch target: March 2027
  • Backward integration project providing scale advantage
  • Ramp-up plan: 80-100% utilization by end of first year
  • Long-term utilization guidance: 80% in-house use, 20% third-party sales
  • Initial production entirely for in-house use due to GMP approval requirements
  • Capex: INR750 crores

US Formulation Strategy

  • Target launch timeline: 2030
  • Products identified: Cefta-avi, Ceftaroline, Ceftolozane-tazobactam (new molecules) plus Cefepime, Ceftriaxone, Cefazolin (older molecules)
  • ANDA filings and DMFs planned using Cefiderocol facility

Integration and Synergies

Focused integration projects with Dhanuka Laboratories underway, with initial benefits expected to become visible in next financial year (FY28).

Capital Expenditure

  • 7-ACA project: INR750 crores
  • Cefiderocol project: USD20-25 million
  • No significant capex budgeted for FY27 beyond current projects

Management Guidance and Commentary

Near-term Priorities

  • Protect and grow core business with cost discipline
  • Improve margins through volumes and product mix
  • Execute capital projects safely and on time

Market Outlook

Pricing and demand conditions in core markets remain competitive. Benefits of merger synergies, product mix improvement, and new projects will emerge progressively rather than all at once. Regulated market demand is cyclical with typically stronger second half performance.

Long-term Opportunities

  • Combined Orchid-Dhanuka platform
  • Backward integration into 7-ACA
  • Cefiderocol access project
  • Exblifep commercialization
  • Selective expansion into regulated finished dose markets